WO2013132083A1 - Dispersion comprenant des corps dispersés, chacun comportant une goutte interne et une membrane - Google Patents
Dispersion comprenant des corps dispersés, chacun comportant une goutte interne et une membrane Download PDFInfo
- Publication number
- WO2013132083A1 WO2013132083A1 PCT/EP2013/054786 EP2013054786W WO2013132083A1 WO 2013132083 A1 WO2013132083 A1 WO 2013132083A1 EP 2013054786 W EP2013054786 W EP 2013054786W WO 2013132083 A1 WO2013132083 A1 WO 2013132083A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- membrane
- dispersion
- phase
- drop
- internal
- Prior art date
Links
- 239000012528 membrane Substances 0.000 title claims abstract description 102
- 239000006185 dispersion Substances 0.000 title claims abstract description 44
- 238000005192 partition Methods 0.000 claims abstract description 20
- 239000012071 phase Substances 0.000 claims description 98
- 239000007788 liquid Substances 0.000 claims description 24
- 229920000867 polyelectrolyte Polymers 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 14
- 239000003921 oil Substances 0.000 claims description 14
- 235000019198 oils Nutrition 0.000 claims description 14
- -1 apolar solvents Chemical class 0.000 claims description 12
- 239000002537 cosmetic Substances 0.000 claims description 7
- 238000005538 encapsulation Methods 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 5
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 5
- 239000008158 vegetable oil Substances 0.000 claims description 5
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 229920002545 silicone oil Polymers 0.000 claims description 4
- 150000004665 fatty acids Chemical class 0.000 claims description 3
- 150000002191 fatty alcohols Chemical class 0.000 claims description 3
- 239000008384 inner phase Substances 0.000 claims description 3
- 239000002480 mineral oil Substances 0.000 claims description 3
- 239000012454 non-polar solvent Substances 0.000 claims description 3
- 230000009974 thixotropic effect Effects 0.000 claims description 3
- 239000011149 active material Substances 0.000 abstract 2
- 239000000243 solution Substances 0.000 description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 238000000034 method Methods 0.000 description 15
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 14
- 239000004094 surface-active agent Substances 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 10
- 230000003204 osmotic effect Effects 0.000 description 9
- 239000000499 gel Substances 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 229920006037 cross link polymer Polymers 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 229920002307 Dextran Polymers 0.000 description 5
- 239000008346 aqueous phase Substances 0.000 description 5
- 150000004676 glycans Chemical class 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 239000006210 lotion Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 239000005017 polysaccharide Substances 0.000 description 5
- 101100493712 Caenorhabditis elegans bath-42 gene Proteins 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 229940008099 dimethicone Drugs 0.000 description 4
- 239000004205 dimethyl polysiloxane Substances 0.000 description 4
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000002562 thickening agent Substances 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001879 gelation Methods 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000003570 air Substances 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000001153 anti-wrinkle effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 239000003093 cationic surfactant Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000006254 rheological additive Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229920005573 silicon-containing polymer Polymers 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229940010747 sodium hyaluronate Drugs 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 229910021653 sulphate ion Inorganic materials 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- AEMOLEFTQBMNLQ-AZLKCVHYSA-N (2r,3s,4s,5s,6r)-3,4,5,6-tetrahydroxyoxane-2-carboxylic acid Chemical compound O[C@@H]1O[C@@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-AZLKCVHYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 235000005254 Allium ampeloprasum Nutrition 0.000 description 1
- 240000006108 Allium ampeloprasum Species 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000000592 Artificial Cell Substances 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 235000004936 Bromus mango Nutrition 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 208000035484 Cellulite Diseases 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 240000007228 Mangifera indica Species 0.000 description 1
- 235000014826 Mangifera indica Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010049752 Peau d'orange Diseases 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 235000009184 Spondias indica Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002318 adhesion promoter Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 1
- 229910001422 barium ion Inorganic materials 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- WQTGWZBJQUHTAW-UHFFFAOYSA-N dodecyl(ethyl)azanium;chloride Chemical compound Cl.CCCCCCCCCCCCNCC WQTGWZBJQUHTAW-UHFFFAOYSA-N 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 239000008169 grapeseed oil Substances 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000118 hair dye Substances 0.000 description 1
- ZWGTVKDEOPDFGW-UHFFFAOYSA-N hexadecylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[NH3+] ZWGTVKDEOPDFGW-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000010408 potassium alginate Nutrition 0.000 description 1
- 239000000737 potassium alginate Substances 0.000 description 1
- MZYRDLHIWXQJCQ-YZOKENDUSA-L potassium alginate Chemical compound [K+].[K+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O MZYRDLHIWXQJCQ-YZOKENDUSA-L 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 229940043267 rhodamine b Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/11—Encapsulated compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/10—General cosmetic use
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/56—Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/60—Particulates further characterized by their structure or composition
- A61K2800/61—Surface treated
- A61K2800/62—Coated
- A61K2800/63—More than one coating
Definitions
- the present invention relates to a dispersion comprising a plurality of bodies dispersed in a continuous phase, each dispersed body having an internal drop formed of an internal phase, the internal drop receiving an active product, each dispersed body comprising, around the internal drop, a membrane formed of an intermediate phase and completely surrounding the internal drop.
- the dispersion according to the invention is intended to stably encapsulate for a significant period of time, for example greater than one week, an active product generally miscible with a continuous phase, for subsequent delivery and / or protection against with respect to molecules present in the external phase.
- the active product is for example a cosmetic active product, a biologically active product or an edible active product.
- dispersions comprising micron or submicron particles have been designed, for example in the pharmaceutical field, in particular for the delivery of anticancer agents parenterally.
- dispersions nevertheless have an encapsulation and retention capacity which can be very limited, in particular when the active product to be encapsulated is hydrophilic.
- the dispersions containing the active products can be complex to prepare and formulate to ensure satisfactory encapsulation rate and stability over time.
- An object of the invention is to provide a dispersion which has improved retention and stability properties, especially for hydrophilic active products, and which is nevertheless easy to manufacture.
- the subject of the invention is a dispersion of the aforementioned type, characterized in that the ratio R1 of the mean thickness of the membrane to the average transverse dimension of the active volume delimited by the internal drop and the membrane is greater than 0.05, and is advantageously less than 0.5, and in that the ratio R2 of the partition coefficient of the active product between the intermediate phase forming the membrane and the internal phase forming the internal drop on the viscosity of the membrane is less than at 1 s "1 .Pa " 1 .
- the dispersion according to the invention may comprise one or more of the following characteristics taken singly or in any technically possible combination:
- the ratio R1 of the mean thickness of the membrane to the average transverse dimension of the active volume is between 0.08 and 0.45, especially between
- the ratio R2 of the partition coefficient of the active product between the membrane and the internal drop on the viscosity of the membrane is less than 0.5 s. ⁇ Pa ⁇ especially less than 0.2 s. " Pa "1 ;
- the active volume of each dispersed body has an average transverse dimension greater than 0.5 mm, in particular between 1 mm and 5 mm;
- the internal drop is formed by an aqueous internal phase, the membrane being formed by an oily intermediate phase;
- the oily phase is formed on the basis of an oil chosen from the group comprising silicone oils, mineral oils, esters of fatty acids and / or of fatty alcohol, vegetable oils, and oils compatible with the esters such as apolar solvents, their mixtures and / or their gelled form;
- the thickness difference of the membrane over the entire external surface of the internal drop is less than 30%;
- each dispersed body comprises an outer envelope surrounding the membrane, the outer envelope having a thickness less than that of the membrane;
- the outer envelope is formed of a gelled polyelectrolyte layer
- the active product is chosen from a cosmetic active product, a biologically active product or an edible active product or their mixtures;
- the internal phase is miscible with the continuous phase
- the intermediate phase is immiscible with the continuous phase.
- the subject of the invention is also the use of a dispersion as defined above for the encapsulation of an active product, in particular of a cosmetic active product for a duration greater than one week, advantageously greater than one month.
- a is miscible with B generally means that the solubility of A in B is greater than 0.01% by weight.
- the term “A is immiscible with B” means that the solubility of A in B is less than 0.05% by weight.
- FIG. 1 is a schematic view of a first dispersion according to the invention disposed in a first container;
- FIG. 2 is an enlarged view of an example of a dispersed body encapsulating an active product in a dispersion according to the invention;
- FIG. 3 is a schematic side view taken in partial section of an exemplary device for manufacturing the visible dispersion in FIG. 1;
- FIG. 4 is a graph illustrating the absorbance in the continuous phase in a dispersion according to the invention, in which an absorbent active product has been encapsulated in the dispersed phase;
- FIG. 5 is a view similar to FIG. 4 for a dispersion according to the invention containing another absorbent active product
- FIG. 6 is a second example of a body dispersed in a dispersion according to the invention.
- a first dispersion 10 according to the invention is illustrated in FIG.
- the dispersion 10 comprises a plurality of bodies 12 dispersed and a continuous phase 14 receiving the dispersed bodies 12.
- the dispersion 10 is received in a container 15.
- each dispersed body 12 has an internal drop 16 formed of an internal phase miscible with the continuous phase 14 and a membrane 18 of liquid encapsulation formed of an intermediate phase, immiscible with the continuous phase 14.
- each dispersed body 12 advantageously comprises an outer envelope 19 surrounding the membrane 18 of the dispersed body 12.
- the dispersion 10 comprises at least one active product 20 received in the internal drop 16, the product 20 being encapsulated in the dispersed body 12.
- the continuous phase 14 is an aqueous phase.
- it contains at least 60% by weight of water.
- the continuous phase 14 is viscous, which may be in the form of an aqueous gel or cream having a viscosity greater than 1000 mPa.s.
- This viscosity is generally between 2000 mPa.s and 20000 mPa.s, in particular between 4000 mPa.s and 15000 mPa.s.
- a Brookfield DV-II viscometer with a spindle of size (No.) 05 was used. About 150 g of solution were placed in a beaker of 250 ml volume, having a diameter of about 7 cm. that the height of the volume occupied by the 150 g of solution is sufficient to reach the gauge marked on the mobile. Then, we start the viscometer on a speed of 10 RPM and wait until the value displayed on the screen is stable.
- each dispersed body 12 has a substantially spherical shape.
- the active volume formed by the internal drop 16 and the membrane 18 has a mean transverse dimension of greater than 0.5 mm and less than 8 mm, preferably less than 5 mm.
- the dispersed bodies 12 advantageously have a monodisperse distribution.
- the polydispersity in size of the dispersed bodies 12, measured by the coefficient of variation C v consisting of the ratio of the standard deviation of the average transverse dimension of the dispersed bodies 12 to the mean transverse mean dimension of the dispersed bodies 12 is less than 10%, and in particular between 1% and 5%.
- the average cross-sectional dimensions De of each dispersed body 12 and the active volume and the polydispersity are advantageously measured on at least seven bodies 12 using the image processing software "Image J" on the basis of a body image. scattered 12 taken in top view with a digital camera.
- the internal drop 16 is advantageously formed of a phase miscible with the continuous phase 14.
- the internal drop 16 is formed of an aqueous phase comprising at least 70% by weight of water.
- the inner drop 16 advantageously has a spherical shape.
- the inner drop 16 has an elliptical or ovoid shape.
- the viscosity of the internal phase 16 is, for example, less than 50,000 mPa.s and preferably less than 30,000 mPa.s.
- the core 40 is based on a predominantly aqueous phase or on the contrary a predominantly oily phase.
- the internal phase may be gelled in order to suspend solid particles (flakes, pearlescent agents, particles of metal or mineral oxides (silica, carbonates, etc.).
- the osmotic pressure in the internal drop 16 is substantially equal to the osmotic pressure in the external phase 14.
- the difference in osmotic pressure between the internal drop 16 and the external phase 14 is less than 10% of the osmotic pressure in the internal drop 16.
- osmotic pressures are measured by the following method: An osmometer is used (for example the Cryoscopic Osmometer OSMOMAT 030 from Gonotec) to measure the osmotic pressure. A sample of 50 ⁇ l of the continuous phase, or a sample of the internal phase extracted from the capsules, is introduced into a 1.5 ml eppendorf. This eppendorf is engaged on the device. The apparatus then cools the sample until crystallizing the sample. The value obtained from the crystallization temperature then makes it possible to measure the osmotic pressure of the sample in osmol / kg.
- each internal drop 16 may contain one or more cosmetic, biologically active, or edible active products.
- the internal drop 16 comprises a cosmetic active ingredient such as sodium hyaluronate or other moisturizing / repairing molecules, vitamins, enzymes, anti-wrinkle, anti-aging, protective / anti-free radical active ingredients, antioxidants , soothing, softening, anti-irritant, tensor / smoothing, emollient, slimming, anti-cellulite, firming, shaping, draining, anti-inflammatory, depigmenting, whitening, self-tanning, exfoliating, stimulating cell renewal or stimulating cutaneous microcirculation, absorbing or filtering the UV, anti-dandruff.
- a cosmetic active ingredient such as sodium hyaluronate or other moisturizing / repairing molecules, vitamins, enzymes, anti-wrinkle, anti-aging, protective / anti-free radical active ingredients, antioxidants , soothing, softening, anti-irritant, tensor / smoothing, emollient, slimming, anti-cellulite, firming, shaping, draining, anti
- the internal drop 16, beyond a simple solution may for example be a cream, an emulsion, a lotion, a gel and a skin oil (hands, face, feet, etc.), a foundation. (liquid, paste) a preparation for baths and showers (salts, foams, oils, gels, etc.), a hair care product (hair dye and bleach), a cleaning product (lotions, powders, shampoos), a product hair care products (lotions, creams, oils), a styling product (lotions, lacquers, glossines), a product for shaving (soaps, foams, lotions, etc.), a product intended to be applied on the skin. lips, a sun product, a tanning product without sun, a product to whiten the skin, an anti-wrinkle product.
- the internal drop 16 comprises a biologically active product advantageously chosen from anticoagulants, antithrombogenic agents, anti-mitotic agents, anti-proliferation, anti-adhesion, anti-migration agents, cell adhesion promoters, growth factors, antiparasitic molecules, anti-inflammatories, angiogenics, angiogenesis inhibitors, vitamins, hormones, proteins, antifungals, antimicrobial molecules, antiseptics or antibiotics.
- a biologically active product advantageously chosen from anticoagulants, antithrombogenic agents, anti-mitotic agents, anti-proliferation, anti-adhesion, anti-migration agents, cell adhesion promoters, growth factors, antiparasitic molecules, anti-inflammatories, angiogenics, angiogenesis inhibitors, vitamins, hormones, proteins, antifungals, antimicrobial molecules, antiseptics or antibiotics.
- the internal drop 16 contains reagents such as proteins or reagents to form a bioreactor, or to form artificial cells for implants.
- the internal drop 16 contains an edible product.
- the edible products that are suitable for consumption by a human being or an animal are advantageously purees of vegetables or fruits such as mashed mango, pear puree, coconut puree, onion cream, leeks, carrots, or other preparations that can mix several fruits or vegetables.
- it is oils such as a food oil, such as olive oil, soybean oil, grape seed oil, sunflower oil, or any other oil extracted from the plants.
- the inner drop 16 may also include excipients, such as thickeners, or rheology modifiers.
- thickeners are, for example, polymers, cross-polymers, microgels, gums or proteins, including polysaccharides, celluloses, polysaccharides, silicone polymers and co-polymers, colloidal particles (silica, clays). , latex ).
- the internal drop 16 is macroscopic. Its volume is advantageously between 1% and 75% of the total volume of the dispersed body 12 and is in particular between 1% by volume and 60% by total volume of the volume of the dispersed body 12.
- the intermediate membrane 18 is disposed around the internal drop 16.
- the entire outer surface of the inner drop 16 is covered with the intermediate membrane 18, so that the internal drop 16 has no uncovered region.
- the intermediate membrane 18 is immiscible with the internal drop 16.
- the solubility of the intermediate membrane 18 in the internal drop 16 is less than 0.05% by mass, or even less than 0, 02% in mass.
- the membrane 18 is for example formed from one or more oils selected from the group consisting of silicone oils, mineral oils, fatty acid esters and / or fatty alcohol esters, vegetable oils, and oils compatible with esters such as apolar solvents. These oils can be used alone, as a mixture or in the gelled form.
- Intermediate membrane 18 may thus also include excipients, such as thickeners, or rheology modifiers.
- thickeners are, for example, polymers, cross-polymers, microgels, gums or proteins, including polysaccharides, celluloses, polysaccharides, silicone polymers and copolymers, colloidal particles (silica, clays). , latex ).
- Vegetable oil gelation can be performed using Creagel Crystal SUN (Color Creation) or Transgel 1 10PDI (Aiglon).
- the gelation of silicone oil for example dimethicone, can be carried out by adding a silicone crosspolymer gelling agent, for example KSG 15 or USG107A from Shin Etsu.
- the membrane 18 has a substantially constant thickness.
- the maximum thickness variation of the membrane 18 is less than 30% of the average thickness of the membrane 18.
- This thickness variation is for example measured by taking six thickness measurements along three perpendicular axes.
- the dispersed body 12 thus comprises an isotropic structure. This also results from the equilibrium of the osmotic pressure between the outside of the dispersed body 12 and the internal drop 16.
- the thickness of the membrane 18 is for example between 0.1 mm and 3 mm, and in particular between 0.3 mm and 2 mm.
- the membrane 18 generally has a viscosity of less than 200,000 mPa.s and in particular less than 50,000 mPa.s, advantageously less than 30,000 mPa.s, as measured by the method described above.
- the membrane 18 is advantageously liquid.
- the membrane 18 is made based on a thixotropic phase, which is in the liquid and unstructured state when it flows (during the manufacturing process for example), but which is substantially solid or gelled at rest.
- liquid when it flows it is meant that the behavior of the intermediate phase is viscous, that is to say that the deformation of the material does not depend only on the stress applied but also on the duration during which this stress is applied.
- One way to characterize this behavior is by a creep test using a rheometer on the sample, we apply a characteristic stress of the flows involved during the manufacturing and we trace the strain curve as a function of time ( data obtained with the rheometer software). If the curve has a non-zero slope at long times (more than 30 seconds), the intermediate phase can be considered as being liquid. If this slope is zero, the intermediate phase can be considered as solid.
- solid or gelled at rest it is meant that the behavior of the solid intermediate phase or gelled at rest, ie the deformation of the material depends only on the applied stress.
- One way to characterize this behavior is by a creep test using a rheometer, on the sample, a stress is applied characteristic of those undergone by the membrane at rest as a function of time (data obtained with the rheometer software). If the curve has a zero slope at long times (more than 30 seconds), the intermediate phase can be considered as solid. If this slope is non-zero, the intermediate phase can be considered as being liquid.
- the membrane 18 may also contain active products.
- all the phases used may also contain molecules of cosmetic interest such as active agents, dyes, stabilizers, preservatives, modifying agents chosen from the agents of texture, viscosity, pH, and strength. osmotic or refractive index modifiers.
- the ratio R1 of the average thickness e of the membrane 18 to the average transverse dimension of the active volume formed by the internal drop 16 and the membrane 18 is greater than 0.05.
- This ratio R 1 is advantageously between 0.05 and 0.5, preferably between 0.08 and 0.45, and even more preferably between 0.1 and 0.4.
- the ratio R2 of the partition coefficient of the active product 20 contained in the internal drop 16, between the liquid membrane 18 and the internal drop 16, on the viscosity of the membrane 18 is less than 1 s ⁇ .Pa.sup.-1 and is in particular less than 0.5, to be even more preferably less than 0.2 s ⁇ .Pa ⁇ 1 .
- R 1 is between 0.05 and 0.5, and R 2 is less than 1 s -1 .Pa -1 .
- R1 is between 0.08 and 0.45, and R2 is less than 0.5 Pa ⁇ 1 . s ⁇ 1 .
- R1 is between 0.1 and 0.4, and R2 is less than 0.2 Pa " s -1 .
- the inventors have found, in a particularly surprising manner, that the ratios R 1 and R 2 in the abovementioned ranges led to a particularly effective retention of the active product contained in the internal drop 16 by the outer membrane 18, avoiding the risk of leakage through the membrane. 18.
- the average transverse dimension of the active volume of the dispersed body 12 and the thickness e of the membrane 18 can be determined by the following method.
- the samples comprising about ten scattered bodies 12 are deposited on a plate.
- a Vého Discovery VMS 001 camera connected to a computer is placed so that it can observe the sample from above, and thus see the bodies 12 on the plate.
- the color of the plate will be chosen so as to obtain the best contrast between the body 12 and the plate.
- the acquisition software used is Astra Image Webcam Video Grabber. A snapshot is then recorded in order to be able to measure the area of the active volume of the bodies 12 and the area corresponding to the internal drops of the bodies 12.
- the recorded snapshots are subsequently used with ImageJ.
- the area measurements are obtained in pixels, then converted into metric units by using a standard.
- the ratio of the partition coefficient C p of the active product 20 between the membrane 18 and the internal drop 16 is obtained by determining the partition coefficient of this active product 20 between a phase homologous to the intermediate phase constituting the membrane 18 and a homologous phase. to the internal phase constituting the internal drop 16.
- the ratio C p is calculated by the following equation:
- log P octanol / water partition coefficient of a molecule
- An experimental determination is possible by the following method: a precise quantity of the active ingredient is weighed and solubilized in one of the two phases of water or octanol. Two equivalent volumes of the two phases are then contacted with stirring. The concentrations of the active product in each of the two phases are then carried out after thermodynamic equilibrium of the system. This measurement of concentration can for example be carried out by direct measurement of the absorbance, if the molecule absorbs light, or by liquid chromatography. This measurement is carried out for example at 22 ° C.
- the coefficient K is then experimentally determined by the ratio of the concentration of the active ingredient in octanol to that in water.
- the viscosity ⁇ of the membrane 18 is determined by the following method:
- the membrane 18 To measure the viscosity of the membrane, it is possible to extract the membrane 18 with a syringe on several bodies 12, and then perform a measurement as described above. Alternatively, the dispersed bodies 12 are mixed and / or destroyed, and the resulting mixture is centrifuged to separate the oily phase from the aqueous phase. The (oily or aqueous) phase constituting the membrane 18 is then recovered, and a viscosity measurement is carried out as previously described.
- the K coefficient is generally less than 1, especially less than 10 ⁇ 1 , preferably less than 10 ⁇ 2 and the viscosity of the membrane 18 is generally between 0.001 Pa.s and 200 Pa.s, preferably between 0.01 Pa.s and 200 Pa.s.
- the coefficient K ' is generally less than 1, especially less than 10 " , preferably less than 10 -2.
- the viscosity of the membrane 18 is generally between 0.001 Pa.s and 200 Pa.s, preferably between 0.01 Pa.s and 200 Pa.s.
- each dispersed body 12 comprises an outer envelope 19 made of a gelled polymer.
- the outer casing 19 is advantageously formed by a monolayer of a homogenous gelled material.
- the gelled envelope 19 of the bodies 12 comprises a gel containing water and at least one polyelectrolyte reactive with multivalent ions.
- the envelope 19 may further contain a surfactant.
- polyelectrolyte reactive with polyvalent ions means a polyelectrolyte capable of passing from a liquid state in an aqueous solution to a gelled state under the effect of contact with a gelling solution containing multivalent ions such as alkaline earth metal ions selected for example from calcium ions, barium ions, magnesium ions.
- the individual polyelectrolyte chains are substantially free to flow relative to one another.
- An aqueous solution of 2% by weight of polyelectrolyte then exhibits a purely viscous behavior at the shear gradients characteristic of the forming process.
- the viscosity of this solution with no shear is between 50 mPa.s and 10,000 mPa.s advantageously between 3000 mPa.s and 7000 mPa.s, this viscosity at the shear gradients characteristic of the flows involved during the manufacture of the bodies 12 is for example measured using a stress rheometer, or deformation, imposed on the manufacturing temperature, 25 ° C for example.
- a cone-plane geometry with a diameter of between 10 and 50 mm and a cone angle of 2 ° maximum will be used.
- the individual polyelectrolyte chains in the liquid state advantageously have a molar mass greater than 65000 g / mol.
- the individual polyelectrolyte chains together with the multivalent ions form a coherent three-dimensional network which holds the liquid core and prevents its flow.
- the individual chains are held together and can not flow freely relative to each other.
- the viscosity of the formed gel is infinite.
- the gel has a threshold of stress to the flow. This stress threshold is greater than 0.05 Pa.
- the gel also has a modulus of elasticity that is non-zero and greater than 35 kPa.
- the three-dimensional gel of polyelectrolyte contained in the envelope 19 traps water and the surfactant when it is present.
- the mass content of the polyelectrolyte in the envelope 19 is for example between 0.5% and 5%.
- the polyelectrolyte is preferably a biocompatible polymer that is harmless to the human body. It is for example produced biologically.
- polysaccharides synthetic polyelectrolytes based on acrylates (sodium, lithium, potassium or ammonium polyacrylate, or polyacrylamide), synthetic polyelectrolytes based on sulfonates (poly (styrene sulfonate) ) of sodium, for example). More particularly, the polyelectrolyte is selected from an alkaline earth alginate, such as sodium alginate or potassium alginate, gellan or pectin.
- Alginates are produced from brown algae called “laminar”, referred to as “sea weed”.
- Such alginates advantageously have a content of ⁇ -L-guluronate greater than about 50%, preferably greater than 55%, or even greater than 60%.
- the surfactant when present, is preferably an anionic surfactant, a nonionic surfactant, a cationic surfactant or a mixture thereof.
- the molecular weight of the surfactant is between 150 g / mol and 10,000 g / mol, advantageously between 250 g / mol and 1500 g / mol.
- the surfactant is an anionic surfactant
- it is, for example, chosen from an alkyl sulphate, an alkyl sulphonate, an alkyl aryl sulphonate and an alkaline alkyl phosphate. a dialkylsulfosuccinate, an alkaline earth salt of saturated or unsaturated fatty acids.
- These surfactants advantageously have at least one hydrophobic hydrocarbon chain having a number of carbons greater than 5 or even 10 and at least one hydrophilic anionic group, such as a sulphate, a sulphonate or a carboxylate linked to one end of the hydrophobic chain.
- the surfactant is a cationic surfactant
- it is for example chosen from an alkylpyridium or alkylammonium halide salt such as n-ethyldodecylammonium chloride or bromide, cetylammonium chloride or bromide (CTAB) .
- CTLAB cetylammonium chloride or bromide
- These surfactants advantageously have at least one hydrophobic hydrocarbon chain having a number of carbons greater than 5 or even 10 and at least one hydrophilic cationic group, such as a quaternary ammonium cation.
- the surfactant is a nonionic surfactant
- it is for example chosen from polyoxyethylenated and / or polyoxypropylenated derivatives of fatty alcohols, fatty acids, or alkylphenols, arylphenols, or from alkyls glucosides, polysorbates, cocamides .
- the mass content of surfactant in the shell is greater than 0.001% and is advantageously greater than 0.1%.
- the envelope 19 consists exclusively of polyelectrolyte, surfactant when it is present, and water. The sum of the mass contents of polyelectrolyte, surfactant, and water is then equal to 100%.
- the envelope 19 is fine.
- the volume ratio R v of the volume of the core formed by the internal drop 16 and the membrane 18 on the volume of the envelope 19 is greater than 2, and is in particular greater than 5. This ratio R v is advantageously less than at 50.
- the ratio R v is for example between 5 and 10.
- the thickness of the envelope 19 is in particular less than 0.3 mm, and is for example between 0.025 mm and 0.1 mm.
- the envelope 19 has a clean mechanical strength, especially when it is disposed in a liquid such as water or in a gas.
- the casing 19 allows the body 12 to withstand shear and compressive stresses.
- the maximum compressive strength of the body 12 is advantageously greater than 40 mN, especially greater than 90 mN and may in some cases be greater than 200 mN, for example between 400 mN and 600 mN.
- the force is of the order of 50 mN
- the force can be between 100 and 150 mN, for a vegetable oil, the
- the force can be between 150 and 200 mN and for a crosspolymer the force is between 400 and 600 m N.
- This maximum compressive strength is measured by the following method.
- the body 12 is deposited on a precision balance using a piston which advances at a controlled speed (of the order of 2 millimeters / min).
- the scale is connected to a computer with software that records the mass as a function of time. The recorded mass increases as the piston compresses the body 12 until the body 12 bursts.
- the mass measured at the maximum is multiplied by the acceleration of gravity, to obtain the corresponding force.
- the envelope 19 completely covers the intermediate membrane 18.
- the internal drop 16 and the membrane 18 are totally confined within the envelope 19.
- the dispersion 10 is for example manufactured by a method as described in the French application No. 1061404 of the Applicant. This method is for example implemented in an apparatus 30 shown in FIG.
- the apparatus 30 comprises an outer double jacket 32 and an inner duct 34 disposed in the double jacket 32 in order to co-extrude a series of liquid bodies 35.
- Each liquid body 35 comprises an internal drop 16, a membrane 18 surrounding the inner drop 16, the membrane 18 being coated with a film 36 of a first solution 38 of non-gelled polyelectrolyte intended to form the envelope 19 after gelation.
- the apparatus 30 further comprises a gelling assembly of the film 36, formed in this example by a gelling bath 42, disposed under the jacket 32, away from it, and a rinse and rinse bath. storage (not shown).
- the apparatus 30 further comprises means 44 for supplying the first solution
- the double jacket 32 comprises an outer tube 50 and an intermediate tube 52 disposed co-axially in the outer tube 50.
- the outer tube 50 and the inner tube 52 delimit between them an outer annular chamber 54 for circulating the first solution 38.
- the outer annular chamber 54 is connected upstream to the means 44 for supplying the first solution.
- the outer tube 50 and the inner tube 52 extend along a vertical axis A-A '. They open downwards through an opening 56 forming each liquid body 35.
- the inner conduit 34 is disposed in the intermediate tube 52.
- the inner conduit 34 is mounted co-axially in the tube 52 along the axis ⁇ - ⁇ '. It defines, with the intermediate tube 52, an intermediate annular chamber 58 connected upstream to the supply means 46 of intermediate phase.
- the inner duct 34 further delimits internally an internal phase circulation chamber 59 connected upstream to the internal phase supply means 48.
- the lumen 59 of the duct 34 opens with a downstream opening 60 of internal phase distribution which is located substantially at the same level as the opening 56 of drop formation.
- this opening 60 is offset axially with respect to the opening 56.
- the angle formed by the local axis of the inner duct 34, taken at the downstream opening 60 and the inner tube 52, taken at the same opening may be between 0 ° and 90 °.
- the intermediate annular chamber 58 advantageously opens at the same level as the opening 56.
- the supply means 44, 46, 48 each comprise, for example, a syringe pump, a peristaltic pump or other flow-generating pressure generating system such as, for example, a pressure vessel coupled to a flow meter and a control system. flow.
- a first method of manufacturing a series of bodies 12 for a dispersion 10 according to the invention, implemented in the apparatus 30, will now be described.
- the method comprises a step of forming at least one inner drop 16 of internal phase in the intermediate phase, then a step of forming a liquid body 35 consisting of an intermediate phase membrane 18 containing the internal drop 16.
- the membrane 18 is coated with a film 36 of first solution 38 by coextrusion in the apparatus 30.
- the method then comprises a step of dropping the liquid body 35 through a volume of air, and a step of dipping the body 35 in the gelling bath 42, followed by a rinsing / storage step in a rinsing bath.
- the first solution 38 containing the polyelectrolyte to be gelated, the intermediate phase solution, and the internal phase solution are prepared and are introduced respectively into the first solution supply means 38, in the means 46 for supplying the solution.
- intermediate phase and in the means 48 for supplying the internal phase are introduced respectively into the first solution supply means 38, in the means 46 for supplying the solution.
- Active product 20 is received in the inner phase.
- an intermediate phase of appropriate viscosity is chosen so that the ratio R2 defined above is less than 1 s ⁇ .Pa ⁇ or in the ranges defined above. .
- the means 44, 46, 48 are activated to continuously convey the internal phase in the lumen 59 of the duct 34, the intermediate phase in the intermediate annular chamber 58 and the solution 38 of polyelectrolyte to be gelated in the annular chamber outside 54.
- the internal phase 16 in the intermediate phase is formed at the same time as the intermediate phase membrane 18 covered by the film 36 of solution 38. This simultaneous formation takes place directly at the exit of the jacket 32, at the level of the opening 56.
- the respective flow rates of the internal phase, of the intermediate phase, and of the polyelectrolyte solution to be gelled are chosen as a function of the respective dimensions of the internal droplet 16, the membrane 18 and the desired casing 19. In particular, these flows are controlled so that the ratio R1 defined above is greater than 0.05 or in the ranges defined above.
- the relative and independent adjustment of the inflow rates makes it possible to adjust the thickness of the envelope 19, and the relative size of the drop 16 and the membrane 18.
- a substantially spherical liquid body 35 consisting of a membrane 18 containing an internal drop 16, the membrane 18 covered with a film of solution 38 is gradually formed.
- the film 36 of solution 38 completely surrounds the intermediate drop 20.
- the polyelectrolyte contained in the solution 38 is maintained in its ungelled liquid state.
- the body 35 When the weight of the body 35 is greater than its capillary retention force on the jacket 32, the body 35 detaches from the jacket 32 and falls into the gelling bath 42 by gravity, through a volume of air.
- the film 36 of solution to be gelled 38 then comes into contact with the gelling solution contained in the bath 42.
- the individual polyelectrolyte chains present in the solution 38 are connected to each other to form a crosslinked network which traps water and optionally the surfactant contained in the solution. .
- a gelled envelope 19 as defined above and adapted to retain the membrane 18 and the inner drop 16 is thus achieved.
- the envelope 19 has a proper mechanical strength, that is to say that it is able to completely surround the membrane 18 and to retain it to prevent it from diffusing through the envelope 19, even when the body 12 is disposed in a gas such as ambient air.
- each dispersed body 12 is devoid of an outer envelope 19.
- the liquid membrane 18 is directly in contact with the continuous phase 14 throughout its outer surface.
- the internal drop 16 is separated from the continuous phase 14 by the membrane 18.
- the ratios R1 and R2 are in the ranges defined above.
- the bodies 12 are obtained for example by depolymerization of the outer casing 19, after the formation of the body 12 as described in the method of FIG.
- the continuous phase 14 contains at least one compound capable of reacting with the active product present in the inner drop 16.
- the membrane 18 thus protects the active product 20 from contact with this compound.
- a dispersed body 12 is made with an aqueous inner drop 16, an oily intermediate membrane 18, so that the ratio R1 is equal to 0.38.
- a dispersed body 12 having an active volume of average diameter equal to 4.35 mm and a membrane thickness e equal to 1.66 mm.
- the bodies 12 are dispersed in an aqueous continuous phase 14.
- the active product introduced into the internal drop 16 is formed by a dextran polymer having a molecular weight of 2000 k Daltons.
- a membrane 18 with a viscosity equal to 23200 mPa.s (at 10 revolutions per minute) and a thickness equal to 1.66 mm is formed around the internal drop 16.
- This membrane 18 is based on a mixture of oil silicone (Shin Etsu product KF 96A-6cs (dimethicone)) (19% by weight) and a silicone crosspolymer (Shin Etsu product KSG15) formed from a mixture of dimethicone, vinyl dimethicone crosspolymer and cyclopentasiloxane) (81% by weight).
- the partition coefficient K of dextran as measured by the ratio of dextran concentration in octanol to the ratio of dextran concentration in water, is less than 10 -2, so R2 is less than 4.31 X 10 " V Pa " .
- a dispersion 10 comprising dispersed bodies 12 of identical structure to those of the first example is prepared.
- the active product is beef serum albumin. This protein has about 580 amino acids soluble in large amounts in pure water, with a molecular weight of 66.5 k Daltons.
- the partition coefficient C p of this protein is less than 10 "3.
- the ratio R2 is then less than 10 -4.
- FIGS. 4 and 5 respectively show the ratio of the optical absorbance in continuous phase 14 as a function of time for respectively, the dispersion of the first example containing dextran, and for the dispersion of the second example containing albumin of beef serum . As seen in these figures, no leakage of active product is observed after more than a week at a temperature of 50 ° C.
- each body 12 is Rhodamine B, having a molecular weight equal to 479 g / mol, and a partition coefficient equal to 70.8, the ratio R2 is equal to 3.05. and a leak is observed.
- this partition coefficient K is for example determined from the log P coefficient corresponding to the octanol / water partition coefficient of the molecule, which is generally tabulated, with reference to physicochemical conditions. data (for example pH, or temperature), which correspond to those that can be used for the production of dispersed bodies 12.
- the skilled person can naturally and without difficulty choose the viscosity required for the membrane 18, to obtain a ratio R2 less than 1 s ⁇ .Pa ⁇ 1 . If necessary, the viscosity of the intermediate phase for forming the membrane 18 is adjusted by adding viscosity modifying additives, which are well known to those skilled in the art.
- the viscosity of the membrane 18 can be determined at the same temperature as the temperature at which the viscosity of the polyelectrolyte to constitute the outer shell 19 is determined, namely 25 ° C. .
- the device 30 described above allows, in known manner, through the choice of the size of the openings 56, 60 and a flow control system, to precisely control the average thickness of the membrane 18 and the corresponding mean transverse dimension of the active volume delimited by the internal drop 16 and the membrane 18.
- the skilled person is able to make the necessary adjustments to obtain bodies 12 having a ratio R1 greater than 0, 05.
- the membrane 18 is advantageously liquid or made based on a thixotropic phase, without being gelled.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Cosmetics (AREA)
- Colloid Chemistry (AREA)
- Manufacturing Of Micro-Capsules (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/383,186 US10143650B2 (en) | 2012-03-08 | 2013-03-08 | Dispersion intended for encapsulating an active product and associated use |
CN201380012792.8A CN104244909B (zh) | 2012-03-08 | 2013-03-08 | 用于封存活性产物的分散系及相关用途 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1252115A FR2987740B1 (fr) | 2012-03-08 | 2012-03-08 | Dispersion destinee a encapsuler un produit actif et utilisation associee |
FR1252115 | 2012-03-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013132083A1 true WO2013132083A1 (fr) | 2013-09-12 |
Family
ID=47843316
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2013/054786 WO2013132083A1 (fr) | 2012-03-08 | 2013-03-08 | Dispersion comprenant des corps dispersés, chacun comportant une goutte interne et une membrane |
Country Status (4)
Country | Link |
---|---|
US (1) | US10143650B2 (fr) |
CN (1) | CN104244909B (fr) |
FR (1) | FR2987740B1 (fr) |
WO (1) | WO2013132083A1 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015075074A1 (fr) | 2013-11-19 | 2015-05-28 | Capsum | Procédé de préparation de capsules comprenant un coeur liquide et une coque externe |
FR3031914A1 (fr) * | 2015-01-27 | 2016-07-29 | Jerome Bibette | Procede d'encapsulation |
WO2018015197A1 (fr) | 2016-07-20 | 2018-01-25 | Capsum | Série de capsules et procédé de fabrication, composition cosmétique et traitement cosmétique |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2744883B1 (fr) * | 2011-08-15 | 2018-12-26 | The Procter and Gamble Company | Articles de soins personnels ayant de multiples zones contenant des compositions de soins personnels conformes |
FR3057768B1 (fr) * | 2016-10-26 | 2018-12-07 | Capsum | Emulsions doubles comprenant une phase grasse gelifiee |
FR3070858B1 (fr) * | 2017-09-14 | 2020-02-21 | Capsum | Dispersion avec phase grasse dispersee a teneur elevee en pigments |
CN112641130B (zh) * | 2020-12-25 | 2022-08-12 | 福建金闽再造烟叶发展有限公司 | 一种卷烟爆珠质量控制方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0525731A2 (fr) * | 1991-07-31 | 1993-02-03 | Morishita Jintan Co., Ltd. | Capsule sans soudure et son procédé de production |
FR2939012A1 (fr) * | 2008-12-01 | 2010-06-04 | Capsum | Procede de fabrication d'une serie de capsules, et serie de capsules associee |
WO2010070602A2 (fr) * | 2008-12-18 | 2010-06-24 | Firmenich Sa | Microcapsules et leurs applications |
FR2964017A1 (fr) * | 2010-09-01 | 2012-03-02 | Capsum | Procede de fabrication d'une serie de capsules de taille submillimetrique |
WO2012089820A1 (fr) * | 2010-12-31 | 2012-07-05 | Capsum | Serie de capsules comprenant au moins une goutte de phase interne dans une goutte de phase intermediaire et procede de fabrication associe |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4778688A (en) * | 1985-10-11 | 1988-10-18 | Sepracor, Inc. | Production of low-ethanol beverages by membrane extraction |
US5498420A (en) * | 1991-04-12 | 1996-03-12 | Merz & Co. Gmbh & Co. | Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions |
US5300305A (en) * | 1991-09-12 | 1994-04-05 | The Procter & Gamble Company | Breath protection microcapsules |
RU2480018C2 (ru) * | 2007-06-29 | 2013-04-27 | Нестек С.А. | Стабильные двойные эмульсии |
-
2012
- 2012-03-08 FR FR1252115A patent/FR2987740B1/fr active Active
-
2013
- 2013-03-08 US US14/383,186 patent/US10143650B2/en not_active Expired - Fee Related
- 2013-03-08 CN CN201380012792.8A patent/CN104244909B/zh not_active Expired - Fee Related
- 2013-03-08 WO PCT/EP2013/054786 patent/WO2013132083A1/fr active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0525731A2 (fr) * | 1991-07-31 | 1993-02-03 | Morishita Jintan Co., Ltd. | Capsule sans soudure et son procédé de production |
FR2939012A1 (fr) * | 2008-12-01 | 2010-06-04 | Capsum | Procede de fabrication d'une serie de capsules, et serie de capsules associee |
WO2010070602A2 (fr) * | 2008-12-18 | 2010-06-24 | Firmenich Sa | Microcapsules et leurs applications |
FR2964017A1 (fr) * | 2010-09-01 | 2012-03-02 | Capsum | Procede de fabrication d'une serie de capsules de taille submillimetrique |
WO2012089820A1 (fr) * | 2010-12-31 | 2012-07-05 | Capsum | Serie de capsules comprenant au moins une goutte de phase interne dans une goutte de phase intermediaire et procede de fabrication associe |
Non-Patent Citations (1)
Title |
---|
HOWARD A BARNES: "Thixotropy- a review", JOURNAL OF NON-NEWTONIAN FLUID MECHANICS, ELSEVIER, NL, vol. 70, no. 1, 1 May 1997 (1997-05-01), pages 1 - 33, XP002659998, ISSN: 0377-0257, DOI: 10.1016/S0377-0257(97)00004-9 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015075074A1 (fr) | 2013-11-19 | 2015-05-28 | Capsum | Procédé de préparation de capsules comprenant un coeur liquide et une coque externe |
FR3031914A1 (fr) * | 2015-01-27 | 2016-07-29 | Jerome Bibette | Procede d'encapsulation |
WO2016120308A1 (fr) * | 2015-01-27 | 2016-08-04 | Jérome Bibette | Procédé d'encapsulation |
US20180008948A1 (en) * | 2015-01-27 | 2018-01-11 | Calyxia | Encapsulation method |
US10786798B2 (en) | 2015-01-27 | 2020-09-29 | Calyxia | Encapsulation method |
US11517872B2 (en) * | 2015-01-27 | 2022-12-06 | Calyxia | Encapsulation method |
WO2018015197A1 (fr) | 2016-07-20 | 2018-01-25 | Capsum | Série de capsules et procédé de fabrication, composition cosmétique et traitement cosmétique |
US10940098B2 (en) | 2016-07-20 | 2021-03-09 | Capsum | Series of capsules and method of manufacture, cosmetic composition and cosmetic treatment |
Also Published As
Publication number | Publication date |
---|---|
US20150030648A1 (en) | 2015-01-29 |
CN104244909A (zh) | 2014-12-24 |
US10143650B2 (en) | 2018-12-04 |
FR2987740B1 (fr) | 2014-04-18 |
FR2987740A1 (fr) | 2013-09-13 |
CN104244909B (zh) | 2018-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2013132083A1 (fr) | Dispersion comprenant des corps dispersés, chacun comportant une goutte interne et une membrane | |
EP2370066B1 (fr) | Procede de fabrication d'une serie de capsules, et serie de capsules associee | |
EP2885085B1 (fr) | Elément de délivrance d'une composition fluide, dispositif de distribution et procédé associés | |
FR2987741A1 (fr) | Kit comprenant deux compositions separees, notamment pour une application cosmetique | |
WO2012089820A1 (fr) | Serie de capsules comprenant au moins une goutte de phase interne dans une goutte de phase intermediaire et procede de fabrication associe | |
WO2013113830A1 (fr) | Procédé de préparation de capsules rigidifiées | |
FR3012050A1 (fr) | Procede de formation d'une dispersion comprenant des gouttes, et appareil associe | |
WO2012120043A2 (fr) | Procédé de formation de gouttes d'une première phase dispersées dans une deuxième phase sensiblement immiscible avec la première phase | |
EP3487476B1 (fr) | Série de capsules et procédé de fabrication, composition cosmétique et traitement cosmétique | |
EP3233045A1 (fr) | Dispersions stables comprenant des gouttes d'agent parfumant | |
WO2015075074A1 (fr) | Procédé de préparation de capsules comprenant un coeur liquide et une coque externe | |
WO2011086331A2 (fr) | Procédé de fabrication de capsules avec une hauteur de chute contrôlée. | |
WO2019002579A1 (fr) | Composition triphasique | |
FR3086866A1 (fr) | Kit comprenant deux compositions separees, notamment pour une application cosmetique | |
EP3331617B1 (fr) | Composition cosmetique exfoliante comprenant des morceaux d'agrumes confits | |
FR3072026B1 (fr) | Ensembles de particules, procedes de preparation et kits les comprenant | |
FR3044223A1 (fr) | Composition cosmetique et utilisation | |
WO2024056706A1 (fr) | Procédé de formation d'une dispersion comprenant des gouttes, et appareil associé | |
WO2014195268A1 (fr) | Vanne à boisseau, dispositif de dosage d'un fluide et procédé de dosage associés | |
WO2024213706A1 (fr) | Dispersion cosmétique stabilisée par suspension stérique | |
WO2023094513A1 (fr) | Emulsion millimétrique bi-phasique | |
FR3145868A1 (fr) | Composition aqueuse gélifiée fluide sans carbomère et procédé de fabrication associé | |
WO2024213703A1 (fr) | Dispersion cosmetique parfumante stabilisee par suspension sterique | |
FR2705230A1 (fr) | Compositions cosmétiques contenant des microcapsules qui comprennent des cristaux liquides d'ester cholestérylique. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13708187 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14383186 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112014022101 Country of ref document: BR |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 13708187 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 112014022101 Country of ref document: BR Kind code of ref document: A2 Effective date: 20140905 |